KR20250083557A - Ahr 효능제 - Google Patents

Ahr 효능제 Download PDF

Info

Publication number
KR20250083557A
KR20250083557A KR1020257015398A KR20257015398A KR20250083557A KR 20250083557 A KR20250083557 A KR 20250083557A KR 1020257015398 A KR1020257015398 A KR 1020257015398A KR 20257015398 A KR20257015398 A KR 20257015398A KR 20250083557 A KR20250083557 A KR 20250083557A
Authority
KR
South Korea
Prior art keywords
compound
mixture
pharmaceutically acceptable
acceptable salt
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257015398A
Other languages
English (en)
Korean (ko)
Inventor
마이클 벨
조엘 캘빈
셰릴 카슨
레이시 쇼비뉴-하인스
크리스천 클라크
프랭크 도어시
더글라스 거너트
스티븐 그린
윌리엄 맥밀런
안토니오 나바로
존 리조
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20250083557A publication Critical patent/KR20250083557A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020257015398A 2022-11-15 2023-11-03 Ahr 효능제 Pending KR20250083557A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263425442P 2022-11-15 2022-11-15
US63/425,442 2022-11-15
PCT/US2023/078633 WO2024107555A1 (en) 2022-11-15 2023-11-03 Ahr agonists

Publications (1)

Publication Number Publication Date
KR20250083557A true KR20250083557A (ko) 2025-06-10

Family

ID=89121650

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257015398A Pending KR20250083557A (ko) 2022-11-15 2023-11-03 Ahr 효능제

Country Status (17)

Country Link
US (1) US20240199608A1 (https=)
EP (1) EP4619401A1 (https=)
JP (2) JP7577819B2 (https=)
KR (1) KR20250083557A (https=)
CN (1) CN120225518A (https=)
AR (1) AR131070A1 (https=)
AU (1) AU2023382389A1 (https=)
CL (1) CL2025001421A1 (https=)
CO (1) CO2025005456A2 (https=)
CR (1) CR20250175A (https=)
DO (1) DOP2025000111A (https=)
IL (1) IL320832A (https=)
JO (1) JOP20250109A1 (https=)
MX (1) MX2025005566A (https=)
PE (1) PE20251588A1 (https=)
TW (2) TW202523664A (https=)
WO (1) WO2024107555A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240124A1 (en) * 2024-05-14 2025-11-20 Eli Lilly And Company Processes for preparing enantiomeric compounds and related molecules
CN120904199B (zh) * 2025-09-30 2026-03-06 上海泽德曼医药科技有限公司 具有稠环结构的化合物及其在医药上的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2510528A1 (de) * 1975-03-11 1976-09-23 Hoechst Ag Benzimidazo-/1,2-a/-chinoline und verfahren zu ihrer herstellung
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
IE52670B1 (en) 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
CN1149214C (zh) 1998-12-04 2004-05-12 东丽株式会社 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂
ATE463482T1 (de) 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
AU2004220176A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
JP2007506788A (ja) * 2003-09-26 2007-03-22 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｈｃｖ感染阻害剤とその使用法
PL1753427T3 (pl) * 2004-05-28 2008-09-30 Janssen Pharmaceutica Nv Zastosowanie podstawionych pochodnych chinoliny do leczenia chorób wywoływanych przez prątki lekooporne
WO2007074491A1 (en) 2005-12-28 2007-07-05 Universita Degli Studi Di Siena HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
WO2008014307A2 (en) 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
WO2018171602A1 (zh) 2017-03-21 2018-09-27 正大天晴药业集团股份有限公司 用于ido和tdo双重抑制剂的脲类化合物
US12312337B2 (en) * 2019-05-10 2025-05-27 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
AR126963A1 (es) * 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr

Also Published As

Publication number Publication date
PE20251588A1 (es) 2025-06-16
TW202523664A (zh) 2025-06-16
AR131070A1 (es) 2025-02-12
IL320832A (en) 2025-07-01
US20240199608A1 (en) 2024-06-20
JP2025032072A (ja) 2025-03-11
TW202434583A (zh) 2024-09-01
JOP20250109A1 (ar) 2025-05-13
WO2024107555A1 (en) 2024-05-23
CL2025001421A1 (es) 2025-08-18
DOP2025000111A (es) 2025-06-15
EP4619401A1 (en) 2025-09-24
JP7577819B2 (ja) 2024-11-05
AU2023382389A1 (en) 2025-05-15
CN120225518A (zh) 2025-06-27
JP2024072283A (ja) 2024-05-27
CO2025005456A2 (es) 2025-05-19
CR20250175A (es) 2025-05-27
TWI870104B (zh) 2025-01-11
MX2025005566A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
CA3081790C (en) Macrocyclic compounds as trk kinase inhibitors and uses thereof
CA3210332A1 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
JP2025520934A (ja) Ｐｒｍｔ５阻害剤及びその使用
CN114539223A (zh) 一种含芳基并氮杂七元环类化合物及其制备方法与应用
US20040167030A1 (en) Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
JP2025032072A (ja) Ａｈｒアゴニスト
JP2019520396A (ja) Ｒｏｃｋ阻害剤としてのスピロ縮合環尿素
WO2007032466A1 (ja) 複素環化合物、その製造方法並びに用途
JP2021510151A (ja) アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための１，３，４，５−テトラヒドロ−２ｈ−ピリド（４，３−ｂ）インドール誘導体
TWI829325B (zh) Ahr促效劑
AU2002360618A1 (en) Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
JP2025500886A (ja) 大環状ｂｔｋ阻害剤
CA3127993A1 (en) Imidazopyridine derivative compounds and use of same
KR20170129810A (ko) 치환된 트리시클릭 헤테로시클릭 화합물
AU2003297565A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
KR20250080854A (ko) Pi3k 억제제로서의 이소퀴놀론
KR20180049056A (ko) 삼환식 축합피리딘-2－온 유도체 및 이들의 brd4 저해제로서의 용도
WO2015064714A1 (ja) オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
TWI899220B (zh) 作為trpv4拮抗劑之嘧啶-4(3h)-酮衍生物
JP7523480B2 (ja) ヒドラゾンアミド誘導体及びその抗骨粗鬆症薬の調製における応用
KR20250095720A (ko) Ahr 효능제
CA3222404A1 (en) Heterocyclic jak inhibitor
JP2024501281A (ja) Ｉｒａｋ４阻害剤としての２ｈ－インダゾール誘導体及び疾患の治療におけるそれらの使用
US6833374B2 (en) Dihydropyrazolo[3,4-d]thieno[2,3-B]pyridinone inhibitors of B7-1
CA2909735C (en) Tricyclic triazolic compounds as sigma receptors ligands

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701